New drug combo shows promise for Hard-to-Treat cancers

NCT ID NCT07169994

Recruiting now Disease control Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new drug called YL202 combined with other anti-cancer medicines (toripalimab or furmonertinib) in people with advanced solid tumors, including breast and lung cancer. The goal is to find safe doses and see if the combination shrinks tumors. About 414 adults aged 18-75 who have tried standard treatments are being recruited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: YL202 (a drug) combined with toripalimab or furmonertinib mesilate
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is an early-phase trial (phase Ib/II) with a small number of participants, so the safety and effectiveness are not yet proven. There is a risk of side effects, and the combination may not work for all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS BREAST CANCER NON-SMALL CELL LUNG CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Affiliated Hospital Of Hebei University
NOT_YET_RECRUITING

Baoding, Hebei, 71051, China
Affiliated Zhongshan Hospital Dalian University
NOT_YET_RECRUITING

Dalian, Liaoning, 116001, China
Affiliated Zhongshan Hospital Dalian University
NOT_YET_RECRUITING

Jinan, Shandong, 250117, China
Anhui Provincial Hospital(The First Affiliated Hospital of Ustc)
NOT_YET_RECRUITING

Hefei, Anhui, 230001, China
Anyang Cancer Hospital
NOT_YET_RECRUITING

Anyang, Henan, 455100, China
Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 201321, China
Fujian Cancer Hospital
NOT_YET_RECRUITING

Fuzhou, Fujian, 350014, China
Ghang xi Medical University Cancer Hospital
NOT_YET_RECRUITING

Nanning, Guangxi, 530028, China
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITING

Harbin, Heilongjiang, 150081, China
Jiangsu Province Hospital（The First Affiliated Hospital With Nanjing Medical University, Jiangsu Women And Children Health Hospital)
NOT_YET_RECRUITING

Nanjing, Jiangsu, 210029, China
Jiangxi Cancer Hospital
NOT_YET_RECRUITING

Nanchang, Jiangxi, China
Liaoning cancer hospital &institute
NOT_YET_RECRUITING

Shenyang, Liaoning, 110042, China
Meizhou People's Hospital（Huangtang Hospital）Meizhou Academy of Medical Sciences
NOT_YET_RECRUITING

Meizhou, Guangdong, 514031, China
Shanxi Cancer Hospital
NOT_YET_RECRUITING

Taiyuan, Shanxi, 30013, China
Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital
NOT_YET_RECRUITING

Sichuan, Sichuan, 610072, China
Sun Yat-sen University Cancer Center
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510555, China
The First Affiliated Hospital of Henan University of Science and Technology
NOT_YET_RECRUITING

Luoyang, Henan, 471023, China
The First People's Hospital of Changde City
NOT_YET_RECRUITING

Changde, Hunan, 415000, China
Tianjin Cancer Hospital Airport Hospital
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, 300300, China
Xiangyang Central Hospital
NOT_YET_RECRUITING

Xiangyang, Hubei, 441138, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.